EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure

Simone Pasquale Crispino iD, Annunziata Nusca, Aurora Ferro, Riccardo Cricco, Martina Ciancio, Andrea Segreti iD, Ilaria Cavallari, Mario Sabatino, Luciano Potena, Gian Paolo Ussia iD, Francesco Grigioni

Biomolecules · 10.11.2025 · 15 (11) · 1574

DOI: 10.3390/biom15111574 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 10.11.2025. Verfasst von Simone Pasquale Crispino und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy. Hauptthemen laut MEDLINE: Heart Failure, Glucagon-Like Peptide-1 Receptor Agonists, Stroke Volume. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 receptor agonists (GLP1-RAs) have demonstrated significant cardiometabolic benefits, particularly in patients with type 2 diabetes and obesity. Their role in heart failure (HF) is gaining increasing attention, with growing evidence supporting their efficacy in HF with preserved ejection fraction (HFpEF). Recent trials have shown that semaglutide improves symptoms, functional capacity, and weight loss in patients with HFpEF. However, these trials did not demonstrate a reduction in HF hospitalizations or mortality. In contrast, tirzepatide has revealed a significant reduction in cardiovascular death and worsening HF events in patients with obesity-related HFpEF, suggesting broader cardioprotective effects. Concordantly, the benefit of GLP1-RAs in the setting of HF with reduced ejection fraction (HFrEF) remains uncertain. Although their mechanisms suggest potential advantages, particularly for patients with a cardiometabolic phenotype, clinical evidence supporting improvements in major clinical outcomes is lacking. Additionally, concerns regarding risk of increased HF hospitalizations, fluid retention and arrhythmic risk have led to a cautious approach in this population. As HF management continues to evolve, GLP1-RAs emerge as a promising yet complex therapeutic option. This review synthesizes the current evidence, highlights key knowledge gaps, and explores how these medications might be integrated into guideline-directed medical therapy (GDMT) to determine their optimal role across the LVEF spectrum in HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureGlucagon-Like Peptide-1 Receptor AgonistsStroke VolumeHumansGlucagon-Like Peptide-1 ReceptorVentricular Function, LeftDiabetes Mellitus, Type 2Glucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

cardio-kidney-metabolic syndromecardiometabolic diseasecardiovascular preventionglucagon-like peptide 1 receptor agonistsheart failureheart failure with preserved ejection fractionheart failure with reduced ejection fraction

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.
  • Department of Medicine and Surgery, Fondazione Policlinico Campus Bio-Medico, 00128 Rome, Italy.
  • Department of Biomedical Engineering, Intelligent Technology Laboratory for Health and Wellbeing, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.
  • Department of Movement, Human and Health Sciences, University of Rome "Foro Italico", 00135 Rome, Italy.
  • Heart Failure and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

ORCID-Profile: Simone Pasquale Crispino, Andrea Segreti, Gian Paolo Ussia

Zitieren

APA

Crispino, S. P., Nusca, A., Ferro, A., Cricco, R., Ciancio, M., Segreti, A., Cavallari, I., Sabatino, M., Potena, L., Ussia, G. P., & Grigioni, F. (2025). Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure. Biomolecules, 15(11), 1574. https://doi.org/10.3390/biom15111574

Vancouver

Crispino SP, Nusca A, Ferro A, Cricco R, Ciancio M, Segreti A, et al. Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure. Biomolecules. 2025;15(11):1574. doi:10.3390/biom15111574

BibTeX
@article{Crispino2025,
  author = {Crispino, Simone Pasquale and Nusca, Annunziata and Ferro, Aurora and Cricco, Riccardo and Ciancio, Martina and Segreti, Andrea and Cavallari, Ilaria and Sabatino, Mario and Potena, Luciano and Ussia, Gian Paolo and Grigioni, Francesco},
  title = {Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure},
  journal = {Biomolecules},
  year = {2025},
  volume = {15},
  number = {11},
  pages = {1574},
  doi = {10.3390/biom15111574}
}
Kostenlos starten →